Application of ostalgia tincture in preparation of medicine for treating synovitis

Abstract

The invention belongs to the technical field of new application of ostalgia tincture, and provides application of ostalgia tincture in preparation of medicine for treating synovitis. Experimental results show that the ostealgia tincture can significantly reduce IL-1beta and TNF-alpha proinflammatory factors in rabbit knee joint synovial cells, can significantly inhibit inflammatory cell infiltration of rat ankle joint synovial, synovial macrophage A-type cell proliferation and synovial hyperplasia, and has application prospects in preparation of the medicine for treating synovitis.

Description

Technical Field

[0001] The invention belongs to the technical field of new applications of Gutongling tincture, and in particular relates to the application of Gutongling tincture in preparing a medicine for treating synovitis. Background Art

[0002] The synovium is a layer of membranous tissue surrounding the joints. It can secrete synovial fluid, reduce friction on the joint surfaces, prevent surface adhesion, provide nutrients to the articular cartilage, and excrete waste.

[0003] Synovitis refers to a joint disease in which the synovium is stimulated and inflamed, resulting in an imbalance in the secretion and absorption of fluid, forming effusion. It can occur in all joints of the body, but is more common in the knee joint. The main symptoms of synovitis include joint swelling and pain, weakness, localized tenderness, difficulty in flexion and extension, and poor mobility.

[0004] The occurrence of synovitis is mainly related to the following factors: (1) Acute trauma and chronic strain: such as external impact, sprain, surgery, excessive or improper use of joints, etc., which cause damage and rupture of the synovial membrane of the joints, resulting in traumatic synovitis; (2) Joint degeneration and bone hyperplasia: more common in the elderly. With the increase of age, the bones and joints undergo degenerative changes, or bone hyperplasia occurs, resulting in mechanical and biochemical stimulation, followed by inflammatory reactions such as synovial edema and effusion; (3) Infection: Studies have found that some patients with synovitis have infectious lesions in their bodies, such as otitis media, respiratory tract infections, periosteal tuberculosis infections, etc.; (4) Other diseases: rheumatism, pigmented villonodular diseases, etc. are also related to synovitis.

[0005] At present, Western medicine treats synovitis by injecting drugs into the joints, extracting synovial fluid or applying hot compresses and pain relief. Its disadvantages are: long treatment cycle, strong dependence, short-lasting effect and recurrence. Traditional Chinese medicine also has many external medicines, but most of them are not very effective and there is a possibility of recurrence.

[0006] Gutongling tincture is a Chinese patent medicine for external use, the main ingredients of which are Artemisia sibiricum, dried ginger, dragon's blood, frankincense, myrrh, and borneol. Among them, Artemisia sibiricum has the effects of dispelling wind, removing dampness, and relieving pain, and has a strong analgesic effect on the pain caused by stagnation of joint meridians. Borneol and dragon's blood have the effects of anti-inflammatory, analgesic, and swelling, and can relieve inflammation and swelling. Frankincense and myrrh have the effects of promoting blood circulation, relieving pain, reducing swelling and promoting tissue regeneration. The combination of the two medicines can enhance the effects of promoting blood circulation, dispersing blood stasis and dredge menstruation. Dried ginger has the effect of warming the meridians and dispersing cold, which can enhance the penetration of drugs through the meridians in the joints.

[0007] The whole formula of Gutongling Tincture has the effects of warming the meridians and dispelling cold, dispelling wind and activating blood circulation, unblocking meridians and relieving pain. It can be used to treat lumbar and cervical vertebrae bone hyperplasia, osteoarthritis, scapulohumeral periarthritis, and rheumatoid arthritis. Summary of the invention

[0008] In view of the above-mentioned deficiencies in the prior art, the object of the present invention is to provide an application of Gutongling tincture in the preparation of a drug for treating synovitis.

[0009] In order to achieve the above object, the solution adopted by the present invention is:

[0010] The invention provides application of Gutongling tincture in preparing medicine for treating synovitis.

[0011] Furthermore, in a preferred embodiment of the present invention, the dosage form of the drug includes a solution, an ointment, an emulsion, a gel, a film coating and an aerosol.

[0012] Furthermore, in a preferred embodiment of the present invention, synovitis includes acute synovitis and chronic synovitis.

[0013] The beneficial effect of the use of the Gutongling tincture provided by the present invention in the preparation of drugs for treating synovitis is as follows: experimental results show that the Gutongling tincture can significantly reduce the IL-1β and TNF-α pro-inflammatory factors in the synovial cells of the rabbit's knee joints, and can significantly inhibit the inflammatory cell infiltration, synovial macrophage type A cell proliferation and synovial hyperplasia of the rat ankle joint synovium, and has application prospects in the preparation of drugs for treating synovitis. DETAILED DESCRIPTION

[0014] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0015] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0016] Example 1

[0017] Experimental animals: 24 healthy Japanese big-eared rabbits, male, 3-4 months old, weight 2.2-2.8 kg, provided by Chengdu Dashuo Experimental Animal Co., Ltd., license number: SCXK (Chuan) 2019-031. Adaptive feeding in a single cage for 3 days. The treatment of animals during the experiment complies with the requirements of the Guiding Opinions on Treating Laboratory Animals Well issued by the Ministry of Science and Technology.

[0018] Experimental methods:

[0019] (1) Establishment of rabbit knee synovitis model: 0.3 ml of 4% papain solution was injected into the right knee joint cavity of the rabbit on the 1st, 4th and 7th days of the experiment, followed by observation for 1 week. On the 14th day of the experiment, the establishment of the rabbit knee synovitis model was observed to determine whether it was successful.

[0020] (2) Grouping: The experimental animals were randomly divided into a control group, a model group, and a Gutongling tincture group, with 8 animals in each group. The animals in the control group moved freely without intervention; the model group and the Gutongling tincture group established a knee synovitis model. After modeling, the Gutongling tincture group was given the corresponding drug (the dosage of the Gutongling tincture group was 0.3 mg / kg) applied to the right affected knee joint of the rabbit, with a thickness of about 4 mm, fixed with gauze strips to prevent falling off, and applied for 4 hours each time, once a day, for 10 consecutive days. The control group and the model group were not given drug treatment, and the knee joint was only fixed with gauze for 4 hours.

[0021] (3) Specimen collection and testing: On the 11th day after drug treatment, all experimental animals were killed by air embolization of the ear vein. Synovial tissue extraction: The skin was incised on the anterior midline of the right knee joint, the joint capsule was cut along the medial and lateral edges of the patella, the quadriceps and patellar ligament tissues were transected above the patella to expose the knee joint, and about 0.15 g of synovial membrane and infrapatellar fat pad tissue were cut, rinsed with distilled water, and stored in a -80℃ refrigerator to measure the concentrations of IL-1β and TNF-α in the specimens.

[0022] (4) Observation indicators:

[0023] General situation: observe the animal's activities, mental state and survival of each group.

[0024] IL-1β and TNF-α detection: The concentrations of IL-1β and TNF-α in the synovial tissue were determined by ELISA according to the operating procedures of the relevant kits.

[0025] (5) Statistical methods: SPSS 19.0 software was used for statistical analysis. The differences were considered statistically significant when P < 0.05.

[0026] Experimental results:

[0027] (1) General condition: After the model was established, the rabbits in the model group and Gutongling tincture group had swelling of the right knee joint, poor mental state, loss of appetite, and reduced activity. After drug intervention, the Gutongling tincture group gradually returned to normal in all aspects.

[0028] (2) The results of IL-1β and TNF-α detection are shown in Table 1:

[0029] Table 1

[0030] Group IL-1β / (pg / ml) TNF-α / (pg / ml) Control group 8.82±1.04 16.08±1.34 Model Group <![CDATA[18.13±1.23 ** ]]> <![CDATA[22.21±1.15 ** ]]> Gutongling Tincture Group <![CDATA[9.05±1.31 # ]]> <![CDATA[18.12±1.04 # ]]>

[0031] Note: Compared with the control group, ** P<0.01; compared with the model group, #P<0.05.

[0032] As shown in Table 1, compared with the control group, the concentrations of IL-1β and TNF-α in the synovial tissue of the model group were significantly increased (P < 0.01), and compared with the model group, the concentrations of IL-1β and TNF-α in the Gutongling tincture group were significantly reduced (P < 0.05). This shows that Gutongling tincture can significantly reduce the IL-1β and TNF-α pro-inflammatory factors in synovial cells, and the topical treatment of synovitis is effective.

[0033] Example 2

[0034] Experimental animals: 18 clean-grade Wistar rats, male, 2-3 months old, weighing 180-220 g, purchased from Chengdu Dashuo Experimental Animal Co., Ltd., license number: SCXK (Sichuan) 2019-028.

[0035] Experimental method: 18 rats were randomly divided into 3 groups, 6 rats in each group, namely normal group, model group, and Gutongling tincture group. Bovine type II collagen was dissolved in 0.1mmol / L acetic acid, and fully mixed with Freund's complete adjuvant at a ratio of 2mg / ml in a ratio of 1:1 for emulsification. Except for the normal group, it was injected at the base of the tail of the rats in the remaining groups (0.2mL per injection per rat). Arthritis was induced 11-16 days after collagen immunization, and the inflammation lasted for 3-4 weeks after the onset of the disease. The drug was administered on the 10th day after modeling. Before administration, the abdomen and legs of the rats in the normal group, model group, and Gutongling tincture group were depilated, and the depilatory range of the abdomen was about 2×3cm 2 , the drug was administered to the ankle joint, knee joint and abdominal hair removal of each rat. The dosage of Gutongling tincture group was 0.9mg / kg, and the normal group and model group were given 0.9mg / kg of normal saline, which was applied to the ankle joint and abdominal hair removal of each rat to allow it to be fully absorbed. The drug was administered continuously for 10 days, once in the morning and evening every day. One hour after the last administration, the rats were decapitated, the joint synovium was separated, and the synovium was subjected to HE pathological sections to determine the effects on inflammatory cell infiltration, macrophage A cell proliferation, and synovial hyperplasia.

[0036] Experimental results: The experimental results are shown in Table 2:

[0037] Table 2

[0038] Group Inflammatory cell infiltration Macrophage A cell proliferation Synovial hyperplasia Total score Normal group 0.15±0.32 0.16±0.36 0±0 0.31±0.68 Model Group <![CDATA[2.45±0.55 ## ]]> <![CDATA[2.36±0.35 ## ]]> <![CDATA[2.02±0.42 ## ]]> <![CDATA[6.83±1.32 ## ]]> Gutongling Tincture Group <![CDATA[0.68±0.35 ** ]]> <![CDATA[0.52±0.41 ** ]]> <![CDATA[0.45±0.32 ** ]]> <![CDATA[1.65±1.08 ** ]]>

[0039] Note: Compared with the blank group, ## P<0.01; compared with the model group, ** P<0.01.

[0040] From the data in Table 2, it can be seen that Gutongling tincture has a significant inhibitory effect on inflammatory cell infiltration, synovial macrophage type A cell proliferation and synovial hyperplasia, indicating that Gutongling tincture can significantly inhibit inflammatory cell infiltration, synovial macrophage type A cell proliferation and synovial hyperplasia, and has a definite effect on the external treatment of synovitis.

[0041] The above experimental results show that Gutongling tincture can significantly reduce the pro-inflammatory factors IL-1β and TNF-α in synovial cells, and can significantly inhibit inflammatory cell infiltration, synovial macrophage type A cell proliferation and synovial hyperplasia, and has application prospects in the preparation of drugs for the treatment of synovitis.

[0042] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Application of Gutongling tincture in the preparation of medicines for the treatment of synovitis.

2. The use of Gutongling tincture according to claim 1 in preparing a medicine for treating synovitis, characterized in that: The dosage forms of the drug include solutions, ointments, emulsions, gels, film coatings and aerosols.

3. The use of Gutongling tincture according to claim 1 in preparing a medicine for treating synovitis, characterized in that: The synovitis includes acute synovitis and chronic synovitis.